ABUS Arbutus Biopharma Corporation

2.55
-0.05  -1.92%
Previous Close 2.60
Open 2.55
Price To book 0.34
Market Cap 139.84M
Shares 54,841,000
Volume 119,274
Short Ratio 2.22
Av. Daily Volume 340,105

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 single dose data released September 2016, multiple dose data released December 12, 2016.
ARB-1467
Hepatitis B (HBV)
Phase 1/2 data released July 2016. Intends to explore partnership opportunities to enable further study
TKM-PLK1
Hepatocellular carcinoma (HCC)

Latest News

  1. Celgene Issues Preliminary 2016 Results, Lifts 2017 View
  2. Ionis, Novartis Ink Deal to Focus on Cardiovascular Treatments
  3. Alexion Blood Disorder Drug Gets Orphan Designation in U.S.
  4. The Medicines Co LDL-Lowering Drug Positive in Phase II
  5. Ultragenyx's (RARE) KRN23 Accepted for Review in the EU
  6. Bayer's sNDA for Stivarga Granted Priority Review in the U.S.
  7. Ionis (IONS) Stock Up on Positive Type II Diabetes Drug Data
  8. Innocoll (INNL) Down on FDA's Refusal to File Xaracoll NDA
  9. Fortress Biotech (FBIO) in Focus: Stock Moves 20.9% Higher
  10. Galena Biopharma Reveals Regulatory Pathway for GALE-401
  11. Intercept Pharmaceuticals (ICPT) Jumps: Stock Rises 9.3%
  12. Anthera (ANTH) Stock Falls on Poor Phase III Sollpura Data
  13. NewLink Genetics (NLNK) Jumps: Stock Adds 10% in Session
  14. Spring Bank (SBPH) Inks 3rd Collaboration Agreement
  15. Alexion Soliris Fails in Phase II/III Delayed Graft Function Study
  16. Bristol-Myers, PsiOxus Ink Deal for Oncolytic Virus Therapy
  17. Celgene (CELG) Otezla Approved in Japan for Two Indications
  18. Spring Bank and Arbutus Biopharma Announce Preclinical Collaboration in Study of Chronic Hepatitis B
  19. Spring Bank and Arbutus Biopharma Announce Preclinical Collaboration in Study of Chronic Hepatitis B
  20. Syndax Pharmaceuticals (SNDX) Looks Good: Stock Up 14.3%